

CRACK IT

# PREDART: Prediction of human developmental and reproductive toxicity through non-mammalian assays

The Syngenta logo consists of the word "syngenta" in a bold, lowercase, blue sans-serif font. A small green leaf icon is positioned above the letter 'g'.

Jayne Wright



Chantal Smulders


# Background

- Current regulatory assessment of fertility and potential effects of chemicals on the developing foetus




- Consequences if a compound is found to be toxic to reproduction and/or development

# New Toxicology Paradigm




National Academy of Sciences – “Toxicity Testing in the 21st Century: A Vision and a Strategy”

# TOX21 for Risk Assessment




# Alternative assays for <sup>CRACK IT</sup> reproductive/developmental toxicity




Zebra fish



# Caenorhabditis elegans




Developmental fate of every cell mapped out



Transparent body and egg assist imaging

CRACK IT

# Dictyostelium (slime mold)



Fruiting bodies

6 hours

10 hours


12 hours

15 hours

24 hours



# Key to Success





## Ultimate goal

- Practical, commercial solutions, including an integration of the available systems
- Understanding of exposure concentrations in the test systems versus those in rats/rabbits and humans
- Adequate assessment of dose-response to enable the integrated test system to be used for risk assessment

# Phase 1

- Exploration of key developmental pathways
- Overlay the information on key developmental pathways from the different test systems and identify common denominators
- Identify conserved pathways across the phyla which could be exploited as surrogate markers for mammalian developmental toxicity potential

# Our contribution to Phase 1

- Knowledge sharing on experiences with non-mammalian assays and substance-testing
- Discussion on an initial compound set and appropriate existing in vivo data for comparison
- Guidance on key industry requirements for model development and incorporation into existing testing strategies

## Phase 2

- Using the knowledge gained from Phase 1, begin to explore perturbations of these key conserved pathways, and their association with developmental perturbations
- Comparison of findings with genomic and other data from existing mammalian studies
- Assessment of compound uptake by non-mammalian systems in relation to physico-chemical properties;
- Determination of the applicability domain (i.e. the types of chemical structures, physicochemical properties and mechanisms of action for which the model can make reliable predictions).
- For physico-chemical properties Lipinski and Tice rules need to apply (Delaney *et al.* 2006; Lipinski 1997, Tice 2001)
- Transfer to a stable medium-throughput system with commercial potential
- **Key success criteria are reproducibility, robustness and reliability**

## Our contribution to Phase 2

- Provision of compounds
- Continued knowledge sharing, including outputs from test systems

## Hints and tips

- Focus on the abilities of your test system
- Find partners with supplemental expertise
- Focus on commercial application as the ultimate goal: KIS (KEEP IT SIMPLE!)